Matthew Weston
Stock Analyst at UBS
(4.29)
# 1,378
Out of 5,004 analysts
340
Total ratings
67.5%
Success rate
9.9%
Average return
Main Sectors:
Stocks Rated by Matthew Weston
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWX: NOVN Novartis AG | Reiterated: Hold | n/a | $119.80 | - | 49 | Sep 17, 2026 | |
| EPA: SAN Sanofi | Reiterated: Hold | n/a | $71.79 | - | 17 | Sep 17, 2026 | |
| LON: GSK GSK plc | Reiterated: Hold | n/a | $1,851.00 | - | 19 | Sep 17, 2026 | |
| SWX: GALD Galderma Group AG | Reiterated: Buy | CHF 200.00 | CHF 163.00 | +22.70% | 13 | Sep 10, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Reiterated: Buy | €62.00 | €50.02 | +23.95% | 24 | Sep 1, 2026 | |
| ETR: MRK Merck KGaA | Downgraded: Hold | €150.00 | €135.00 | +11.11% | 38 | Aug 20, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Upgraded: Buy | €240.00 → €300.00 | €258.30 | +16.14% | 30 | Aug 20, 2026 | |
| EPA: DIM Sartorius Stedim Biotech S.A. | Upgraded: Buy | €220.00 → €260.00 | €212.40 | +22.41% | 17 | Aug 20, 2026 | |
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 17,600p | 12,552p | +40.22% | 68 | Aug 4, 2026 | |
| SWX: ROP Roche Holding AG | Reiterated: Buy | CHF 376.00 | CHF 360.30 | +4.36% | 55 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $125 | $148.78 | n/a | 1 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | CHF 750.00 | CHF 569.20 | n/a | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | €95.00 → €72.00 | €143.30 | n/a | 3 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $310 | $38.80 | n/a | 3 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $145.46 | n/a | 1 | Jul 5, 2017 |
Novartis AG
Sep 17, 2026
Reiterated: Hold
Price Target: n/a
Current: $119.80
Upside: -
Sanofi
Sep 17, 2026
Reiterated: Hold
Price Target: n/a
Current: $71.79
Upside: -
GSK plc
Sep 17, 2026
Reiterated: Hold
Price Target: n/a
Current: $1,851.00
Upside: -
Galderma Group AG
Sep 10, 2026
Reiterated: Buy
Price Target: CHF 200.00
Current: CHF 163.00
Upside: +22.70%
Bayer Aktiengesellschaft
Sep 1, 2026
Reiterated: Buy
Price Target: €62.00
Current: €50.02
Upside: +23.95%
Merck KGaA
Aug 20, 2026
Downgraded: Hold
Price Target: €150.00
Current: €135.00
Upside: +11.11%
Sartorius Aktiengesellschaft
Aug 20, 2026
Upgraded: Buy
Price Target: €240.00 → €300.00
Current: €258.30
Upside: +16.14%
Sartorius Stedim Biotech S.A.
Aug 20, 2026
Upgraded: Buy
Price Target: €220.00 → €260.00
Current: €212.40
Upside: +22.41%
AstraZeneca PLC
Aug 4, 2026
Reiterated: Buy
Price Target: 17,600p
Current: 12,552p
Upside: +40.22%
Roche Holding AG
May 13, 2026
Reiterated: Buy
Price Target: CHF 376.00
Current: CHF 360.30
Upside: +4.36%
Nov 1, 2024
Reiterated: Buy
Price Target: $125
Current: $148.78
Upside: n/a
Jan 27, 2022
Reiterated: Buy
Price Target: CHF 750.00
Current: CHF 569.20
Upside: n/a
Feb 11, 2020
Upgraded: Hold
Price Target: €95.00 → €72.00
Current: €143.30
Upside: n/a
Nov 2, 2018
Reiterated: Hold
Price Target: $310
Current: $38.80
Upside: n/a
Jul 5, 2017
Downgraded: Sell
Price Target: n/a
Current: $145.46
Upside: n/a